SAB Biotherapeutics, Inc. (SABS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-98.8%

$0.04

vs $3.30 price

Levered DCF

$0.07

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

7.11

Safe zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	17×	-1.03×	-0.9×	-1.37×	-12.4×	13.62×	-461.36×
P/B	0.48×	1.35×	0.66×	0.83×	5.54×	7.03×	-191.37×
P/S	0×	26.54×	16.96×	1.07×	3.51×	4.96×	128.19×
EV / EBITDA	4.08×	-1.06×	0.33×	-1.09×	-12.43×	12.76×	-53.74×
Gross margin	0.0%	-262.4%	-67.3%	86.2%	97.3%	100.0%	100.0%
Operating margin	0.0%	-3244.9%	-1700.5%	-121.0%	-22.0%	37.2%	-252.0%
Net margin	0.0%	-2579.0%	-1884.5%	-78.4%	-28.2%	36.4%	-261.1%
Current ratio	9.46×	2.98×	5.45×	1.47×	1.9×	3.11×	2.01×
Debt / equity	0.04×	0.18×	0.1×	0.19×	0.22×	0.21×	-3.31×
Interest coverage	-203.41×	-134.77×	-120.76×	-95.89×	-45.48×	43.82×	-20.24×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	8.8%	-131.3%	-73.6%	-60.3%	-44.5%	51.6%	389.8%
Return on invested capital	-30.0%	-115.9%	-50.8%	-77.5%	-23.2%	43.6%	-56.6%
Return on assets	7.7%	-77.2%	-50.3%	-36.8%	-21.1%	35.6%	-49.9%
Free cash flow yield	-63.3%	-98.7%	-66.6%	-99.8%	-4.2%	-1.0%	-2.2%
Earnings yield	18.4%	-97.2%	-111.1%	-73.0%	-8.0%	7.3%	-2.0%
Enterprise value	$67.7M	$30.9M	-$12.7M	$16.6M	$188.8M	$269.7M	$442.5M
Net debt / EBITDA	-0.27×	0.15×	1.33×	0.6×	1.62×	-0.21×	-0.16×
Cash conversion cycle (days)	-373	-114	-92	-323	-936	136	299